Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsImaging tumor hypoxia to advance radiation oncologyComputational Model for Tumor Oxygenation Applied to Clinical Data on Breast Tumor Hemoglobin Concentrations Suggests Vascular Dilatation and CompressionImaging biomarker roadmap for cancer studiesA priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative UltrasoundNoninvasive Surface Imaging of Breast Cancer in Humans using a Hand-held Optical Imager.Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopyClinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer ImagingPredicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatmentOptical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.Optically measured microvascular blood flow contrast of malignant breast tumors.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Monitoring of tumor response to Cisplatin using optical spectroscopy.Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteriaClinicopathological and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spectroscopy.Broadband optical mammography: chromophore concentration and hemoglobin saturation contrast in breast cancerPoint-of-care and point-of-procedure optical imaging technologies for primary care and global health.Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic ImagingNoncontact diffuse correlation tomography of human breast tumor.Experimental validation of a high-resolution diffuse optical imaging modality: photomagnetic imagingChemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.Feasibility of spatial frequency domain imaging (SFDI) for optically characterizing a preclinical oncology model.Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.High resolution functional photoacoustic tomography of breast cancer.Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity.Detailing renal hemodynamics and oxygenation in rats by a combined near-infrared spectroscopy and invasive probe approach.Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins.Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using quantitative ultrasound, texture, and molecular features.Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.Wearable near-infrared optical probe for continuous monitoring during breast cancer neoadjuvant chemotherapy infusions.Simultaneous In Vivo Fluorescent Markers for Perfusion, Protoporphyrin Metabolism, and EGFR Expression for Optically Guided Identification of Orthotopic Glioma.Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
P2860
Q26822432-12E55B27-3A82-46C4-BF7A-CE9A776DCB9FQ27007862-7C333183-AC17-4DEA-AB0C-63A8627894B5Q27327081-B340E5B2-C15E-4286-BFC6-623262E87F8BQ30242020-8C5189BF-18BA-49DE-B095-045C3B36F9CEQ30358741-6DE578F7-9B74-499D-B6E3-7D5CFF6DE994Q30368541-3940A4C4-1AE8-4C2A-801F-1CF16568EC65Q30375438-FE622022-2BEF-470D-8912-91142AB3F17EQ30399335-0A046127-6167-4DC4-B245-A535558D63E7Q30858109-5796011F-9BFA-4C01-991E-43AA47CBCF9FQ33721539-30B425D5-90A0-4D25-83CA-84016615DF2BQ33812407-B7DEAD3E-EA68-4470-BC04-19F7684E5C20Q33824587-AA4E70D1-7321-44DA-91CC-540987263E58Q33912319-C27F2219-1507-4C93-AB3B-3F8338F86B95Q35000348-ED6F875E-59A1-4928-B2B7-312F3CDC1EE5Q35051916-35CDC294-1CAF-4F25-8220-FD0F2E7724E8Q35187969-6693EFBD-DCAC-45FC-8B8D-B8C8A75D483CQ35207820-2C133854-1D1E-4B2E-9E79-8CB6A7359376Q35806203-4E699031-9338-4D62-AC25-610D2AC85419Q36104503-629FE25A-AF2C-458B-B218-95E515A94560Q36397940-5D95B877-307C-4060-9117-0B15A04B357DQ36480327-107387BF-51D1-4F3A-9DF8-F8E2BD33F8B4Q37270175-36B57FDF-2D14-492D-8CD1-3AE97598E3CFQ37316603-298AF449-F664-445C-B7EE-2B76AACEFD9DQ37324851-241301C3-9248-43BE-9FBF-A643F379379DQ37404430-4BD02587-2861-425C-BC13-21868AF9C7D8Q37671891-72205DA2-271A-4F4C-8827-57181A54FC46Q37710877-802F2505-F6AE-4898-9167-C42EC0EA4632Q38578344-C06B1E85-504E-45CF-914A-0B28E19D36C6Q38731390-DBCAD1B9-51AF-4548-A9B7-21CC6DC28B26Q38770341-FD491346-589D-4F32-B383-4F30A8C6CDFCQ38832422-CB592617-F01E-4542-B73A-61163DDA6586Q40339175-809BBA4A-F224-4D7D-90AE-C1D277A0E9DEQ41701383-BDDEC6B2-71F4-4425-A28C-75501AA7924CQ43181605-64696A9B-7193-4534-BD28-28CB30A40F26Q46093885-FABF6916-BCD9-4EDC-AFC4-6A22B0702154Q47214255-E87348A4-3936-4846-A206-7226083E4D88Q50066888-5C76E637-9A47-44F0-BBE7-5DFE429AC16BQ50324230-EB8C0CAE-77E7-4909-A97E-BD4AEBC185BBQ51114374-0DCD0077-170C-4532-9A37-7DD9DAD5FFC9Q55333524-CE0BC2FF-418F-4753-B3DC-651C8DB2BB5F
P2860
Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@ast
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@en
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@nl
type
label
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@ast
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@en
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@nl
prefLabel
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@ast
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@en
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@nl
P2093
P2860
P1433
P1476
Baseline tumor oxygen saturati ...... oing neoadjuvant chemotherapy.
@en
P2093
Albert Cerussi
Amanda Durkin
Anais Leproux
Darren Roblyer
David Hsiang
John Butler
Rita Mehta
Shanshan Xu
Shigeto Ueda
Thomas D O'Sullivan
P2860
P304
P356
10.1158/0008-5472.CAN-12-0056
P407
P577
2012-07-09T00:00:00Z